Merck and Co., Inc. (MRK) |
| 141.98 -3.47 (-2.39%) 10-13 15:59 |
| Open: | 145.85 |
| High: | 145.9335 |
| Low: | 141.58 |
| Volume: | 8,158,912 |
| Market Cap: | 350,665(M) |
| PE Ratio: | 44.23 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 153.57 |
| Resistance 1: | 147.93 |
| Pivot price: | 145.06 |
| Support 1: | 138.80 |
| Support 2: | 115.48 |
| 52w High: | 156.92 |
| 52w Low: | 82.01 |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
| EPS | 1.260 |
| Book Value | 16.990 |
| PEG Ratio | 2.60 |
| Gross Profit | 20.457 |
| Profit Margin (%) | 4.77 |
| Operating Margin (%) | -0.24 |
| Return on Assets (ttm) | 11.9 |
| Return on Equity (ttm) | 7.0 |
Tue, 13 Oct 2026
48,205 Merck & Co., Inc. $MRK Shares Sold by Courier Capital LLC - MarketBeat
Tue, 13 Oct 2026
Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both? - Yahoo Finance
Tue, 13 Oct 2026
9,102 Merck & Co., Inc. $MRK Shares Acquired by Fragasso Financial Advisors Inc - MarketBeat
Tue, 13 Oct 2026
Paul J. Diaz elected to Merck board, joins Audit and Research Committees - TradingView
Tue, 13 Oct 2026
What Is Next for Merck (NYSE:MRK) in the NYSE Composite? - Kalkine Media
Tue, 13 Oct 2026
Here's What to Expect From Merck & Co.'s Next Earnings Report - Barchart.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |